反应详情

The title product was prepared according to the procedure for Example 102 using diethyl (4-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate (40.0 mg, 0.0944 mmol) and 7-amino-4-(trans-4-ethoxycyclohexyl)-2-methyl-2,3-dihydro-1H-isoindol-1-one (Compound 166B). 1H NMR (CDCl3, 400 MHz): δ=1.19-1.32 (m, 9 H), 1.34-1.46 (m, 2 H), 1.58-1.69 (m, 2 H), 1.92 (d, J=12.88 Hz, 2 H), 2.23 (d, J=10.11 Hz, 2 H), 2.51 (t, J=12.00 Hz, 1 H), 3.14-3.21 (m, 2 H), 3.22 (s, 3 H), 3.31-3.43 (m, 1 H), 3.59 (q, J=6.99 Hz, 2 H), 3.93 (s, 3 H), 3.99-4.12 (m, 4 H), 4.40 (s, 2 H), 6.89 (d, J=8.08 Hz, 1 H), 6.94 (s, 1 H), 7.34 (d, J=8.59 Hz, 1 H), 7.70 (br. s., 1 H), 8.28 (d, J=7.58 Hz, 1 H), 8.39 (br. s., 1 H), 8.62 (d, J=8.59 Hz, 1 H), 10.54 (br. s., 1 H). MS (ES+): m/z 706.26 [MH+] (TOF, polar).